Cargando…

Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature

Extramedullary multiple myeloma (EMM) is an aggressive sub-entity of multiple myeloma (MM). Despite an excellent improvement in survival for most patients with MM over recent decades, the overall survival (OS) of patients with EMM was usually not longer than 3 years. Standard treatment for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Ying, Qian, Zijun, Zhao, Xiujie, Pan, Wenjue, Wei, Xinzheng, Meng, Huimin, Yang, Lin, Xiao, Haowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138324/
https://www.ncbi.nlm.nih.gov/pubmed/34026784
http://dx.doi.org/10.3389/fmed.2021.649824
_version_ 1783695782253166592
author Qian, Ying
Qian, Zijun
Zhao, Xiujie
Pan, Wenjue
Wei, Xinzheng
Meng, Huimin
Yang, Lin
Xiao, Haowen
author_facet Qian, Ying
Qian, Zijun
Zhao, Xiujie
Pan, Wenjue
Wei, Xinzheng
Meng, Huimin
Yang, Lin
Xiao, Haowen
author_sort Qian, Ying
collection PubMed
description Extramedullary multiple myeloma (EMM) is an aggressive sub-entity of multiple myeloma (MM). Despite an excellent improvement in survival for most patients with MM over recent decades, the overall survival (OS) of patients with EMM was usually not longer than 3 years. Standard treatment for patients with EMM has not been established, and their management is particularly challenging. We presented a heavily pretreated young patient with relapsed EMM and refractoriness to a proteasome inhibitor (PI; bortezomib), a next-generation PI (ixazomib), immunomodulatory drugs (IMiDs; lenalidomide), autologous hematopoietic stem cell transplantation (ASCT), and monoclonal antibody (directed against CD38: daratumumab) and indicated that myeloablative haploidentical hematopoietic stem cell transplantation (haploidentical-HSCT) as a salvage treatment of relapse after a chimeric antigen receptor (CAR)-T cell therapy that targeted B-cell maturation antigen (BCMA) (NCT04650724) is feasible. Taken together of the contemporary literature, the promising results on the effect of anti-BCMA CAR-T cell therapy and allogeneic HSCT might present a proof-of-principle for patients with EMM, and therefore, patients with the disease need to be included in future studies.
format Online
Article
Text
id pubmed-8138324
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81383242021-05-22 Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature Qian, Ying Qian, Zijun Zhao, Xiujie Pan, Wenjue Wei, Xinzheng Meng, Huimin Yang, Lin Xiao, Haowen Front Med (Lausanne) Medicine Extramedullary multiple myeloma (EMM) is an aggressive sub-entity of multiple myeloma (MM). Despite an excellent improvement in survival for most patients with MM over recent decades, the overall survival (OS) of patients with EMM was usually not longer than 3 years. Standard treatment for patients with EMM has not been established, and their management is particularly challenging. We presented a heavily pretreated young patient with relapsed EMM and refractoriness to a proteasome inhibitor (PI; bortezomib), a next-generation PI (ixazomib), immunomodulatory drugs (IMiDs; lenalidomide), autologous hematopoietic stem cell transplantation (ASCT), and monoclonal antibody (directed against CD38: daratumumab) and indicated that myeloablative haploidentical hematopoietic stem cell transplantation (haploidentical-HSCT) as a salvage treatment of relapse after a chimeric antigen receptor (CAR)-T cell therapy that targeted B-cell maturation antigen (BCMA) (NCT04650724) is feasible. Taken together of the contemporary literature, the promising results on the effect of anti-BCMA CAR-T cell therapy and allogeneic HSCT might present a proof-of-principle for patients with EMM, and therefore, patients with the disease need to be included in future studies. Frontiers Media S.A. 2021-05-07 /pmc/articles/PMC8138324/ /pubmed/34026784 http://dx.doi.org/10.3389/fmed.2021.649824 Text en Copyright © 2021 Qian, Qian, Zhao, Pan, Wei, Meng, Yang and Xiao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Qian, Ying
Qian, Zijun
Zhao, Xiujie
Pan, Wenjue
Wei, Xinzheng
Meng, Huimin
Yang, Lin
Xiao, Haowen
Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
title Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
title_full Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
title_fullStr Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
title_full_unstemmed Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
title_short Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
title_sort successful treatment of relapsed/refractory extramedullary multiple myeloma with anti-bcma car-t cell therapy followed by haploidentical hematopoietic stem cell transplantation: a case report and a review of the contemporary literature
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138324/
https://www.ncbi.nlm.nih.gov/pubmed/34026784
http://dx.doi.org/10.3389/fmed.2021.649824
work_keys_str_mv AT qianying successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature
AT qianzijun successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature
AT zhaoxiujie successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature
AT panwenjue successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature
AT weixinzheng successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature
AT menghuimin successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature
AT yanglin successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature
AT xiaohaowen successfultreatmentofrelapsedrefractoryextramedullarymultiplemyelomawithantibcmacartcelltherapyfollowedbyhaploidenticalhematopoieticstemcelltransplantationacasereportandareviewofthecontemporaryliterature